Lantern Pharma Announces Up to \$9.25 Million Registered Direct Offering and Strategic AI Platform Spin-Out
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, has entered into a definitive agreement for a registered direct offering with existing holders and a single institutional investor. This significant financing event, combined with a strategic business move involving its AI platform, could have a material impact on shareholder value and share price.
Key Details of the Offering
- Upfront Capital: Lantern will raise approximately \$4.4 million upfront through the sale of 2,135,923 shares of its common stock (or pre-funded warrants in lieu thereof) at \$2.06 per share.
- Warrants for Additional Proceeds: In a concurrent private placement, Lantern will issue unregistered warrants to purchase up to 2,135,923 shares of common stock. These warrants are exercisable at \$2.27 per share—a 10% premium over the offering price. The warrants become exercisable six months after issuance and expire five years from the initial exercise date.
- Total Potential Proceeds: If all warrants are fully exercised for cash, Lantern could raise an additional \$4.85 million, bringing the total gross proceeds to up to \$9.25 million.
- Use of Proceeds: Lantern intends to use the net proceeds from this offering for working capital and general corporate purposes.
- Placement Agent: Rodman & Renshaw LLC is acting as the exclusive placement agent for the offering.
- Expected Closing: The offering is expected to close on or about May 14, 2026, subject to customary closing conditions.
AI Platform Spin-Out: Major Strategic Development
- Creation of New Entity: Lantern plans to spin out its trained AI agent and related technologies and personnel into a new, independent business entity under CEO Mr. Panna Sharma. This AI platform—operationalized as withZeta.ai—will be separated from Lantern’s publicly-traded oncology drug development business.
- Potential New Listing: The company anticipates that this new AI-focused entity could become a newly listed company on a national stock exchange or market, providing shareholders with potential additional value streams.
- Strategic Rationale: By separating the AI business, Lantern aims to access dedicated funding sources and potentially realize valuation multiples independent from its drug development operations.
- Customer Validation: Ryan Lane from Empery Asset Management, whose funds led the financing round, commented positively on the AI platform’s utility for compound viability analysis, suggesting confidence in its commercial prospects.
Key Considerations for Investors
- Potential Share Dilution: The issuance of over 2 million new shares and the potential for an equal number of warrant exercises could increase the outstanding share count, which may have a dilutive effect on existing shareholders.
- Unlocking Value in AI Platform: The planned spin-out and separate public listing of withZeta.ai could unlock significant additional value for shareholders if the AI business achieves expected growth and market adoption.
- Conditionality and Risk: The offering and spin-out are subject to customary closing conditions and market risks. There is no assurance all warrants will be exercised or that the AI spin-out will achieve a public listing or commercial success.
- Regulatory and Market Risks: None of Lantern’s drug candidates or AI-driven products have yet received FDA marketing approval. Commercial success is not guaranteed.
About Lantern Pharma
Lantern Pharma is focused on transforming oncology drug discovery and development using its proprietary AI and machine learning platform, withZeta.ai. The platform leverages billions of data points to identify biomarker signatures and accelerate targeted oncology therapies for difficult-to-treat cancers. Lantern’s pipeline includes small molecule drug candidates and an antibody-drug conjugate program, with a focus on solid tumors and hematologic malignancies.
- Website: www.lanternpharma.com
- LinkedIn: Lantern Pharma on LinkedIn
- X (Twitter): @lanternpharma
Forward-Looking Statements and Risks
This announcement contains forward-looking statements, including the ability to consummate the offering, the use of proceeds, warrant exercises, and the listing of the new AI entity. Key risks include inability to secure further capital, failure of preclinical/clinical programs, lack of FDA approval, and uncertain commercial adoption of withZeta.ai. Investors should review Lantern’s annual report and risk factors for additional details. There can be no assurance forward-looking statements will be achieved.
Investor Contact
- Email: [email protected]
- Phone: +1-972-277-1136
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should consult with their financial advisors and review company filings before making investment decisions. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
